Department of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Int J Clin Oncol. 2023 Dec;28(12):1597-1606. doi: 10.1007/s10147-023-02416-9. Epub 2023 Oct 13.
High-grade parotid carcinoma generally has a poor prognosis, and the histological type is mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), carcinoma ex pleomorphic adenoma (CEPA), or adenoid cystic carcinoma (AdCC) in the majority of cases.
During the 23-year period from September 1999 to December 2022, 250 patients with parotid carcinoma underwent initial treatment and had the histopathological type of their carcinoma. Retrospective study evaluated 111 MEC, SDC, CEPA, or AdCC cases among 134 patients with high-grade parotid carcinoma. We examined pathological and clinical features and prognosis, evaluated factors associated with recurrence, and performed immunohistological examinations.
Pathological and clinical features and factors associated with recurrence were different for each histological type. The 10-year disease-free survival rates were as follows: MEC, 34.9%; SDC, 22.6%; CEPA, 47.1%; and AdCC, 56.3%. Human epidermal growth factor receptor type-2 and androgen receptor were positive in 48% and 56% of patients with SDC, respectively, 38% and 25% of those with CEPA.
Each histological type has its own pathological and clinical features, recurrence types, and tumor activities, suggesting that differentiating between high-grade parotid carcinomas according to histological type will improve diagnosis, and thus prognosis.
高级别腮腺癌预后通常较差，组织学类型多为黏液表皮样癌（MEC）、唾液导管癌（SDC）、癌在多形性腺瘤中（CEPA）或腺样囊性癌（AdCC）。
在 1999 年 9 月至 2022 年 12 月的 23 年期间，250 例腮腺癌患者接受了初始治疗，并对其癌的组织病理学类型进行了分析。回顾性研究评估了 134 例高级别腮腺癌患者中 111 例 MEC、SDC、CEPA 或 AdCC 病例。我们检查了病理和临床特征以及预后，评估了与复发相关的因素，并进行了免疫组织化学检查。
每种组织学类型的病理和临床特征以及与复发相关的因素均不同。10 年无病生存率分别为：MEC 为 34.9%；SDC 为 22.6%；CEPA 为 47.1%；AdCC 为 56.3%。SDC 患者中分别有 48%和 56%的人表皮生长因子受体 2 和雄激素受体阳性，CEPA 患者中分别有 38%和 25%的人表皮生长因子受体 2 和雄激素受体阳性。
每种组织学类型都有其自身的病理和临床特征、复发类型和肿瘤活性，这表明根据组织学类型对高级别腮腺癌进行区分将改善诊断，从而改善预后。
